Daniel P. Gross

@danielpgross.bsky.social

Prof at @DukeFuqua, formerly @HarvardHBS @UCBerkeley. Studying how crisis R&D, tech policy, automation affect firms & economies. http://dpgross.com

📢 Conference announcement! Paolo Surico and I are excited to be organizing this @cepr.org conference on Public Policies for Innovation. If you work in the #Economics of #Innovation and #InnovationPolicy, please submit + spread the word. Non-presenting attendees also invited.

Centre for Economic Policy Research@cepr.org · 11mo ago

#CallForPapers - Conference on Public Policies for Innovation ESRC, London Business School, @fuqua.duke.edu & CEPR invite submissions for a #conference on Public Policies for Innovation at LBS on 19-20 March 2026. cepr.org/events/confe... Organisers: Paolo Surico & @danielpgross.bsky.social #EconSky

Proud to have worked with this crew, especially Justin Walthier and Hana Ryan, who are both legal prodigies. Thanks to @prmalone.bsky.social, Nina Srejovic, and @stanfordlaw.bsky.social for support, and to @patentscholar.bsky.social for making this happen. We hope the court finds the brief helpful.

Lisa L. Ouellette@patentscholar.bsky.social · last yr.

Thanks to @prmalone.bsky.social and his team at the @juelsgaardclinic.bsky.social at @stanfordlaw.bsky.social for filing this amicus brief on behalf of myself, @pierre-azoulay.bsky.social, @danielpgross.bsky.social & @sampat.bsky.social in the NIH indirect costs case papers.ssrn.com/sol3/papers....

This is a thoughtful take worth a full read. Despite all the hot takes I find it hard to have a point of view over the specific faults or appropriate remedies (individual to the author, or systemic) until we know more about what happened.

Tim Bresnahan@timobres.bsky.social · last yr.

#econsky What do we know about “Artificial Intelligence, Scientific Discovery, and Product Innovation” and about MIT's investigation of this paper, which apparently led to expulsion of its author? And what should we change in response. /1

Reviewing the history of US indirect cost recovery policy, presenting new data on indirect cost recovery rates, modeling the effects of a 15 percent cap at the NIH, and evaluating tradeoffs across reform options, from Azoulay, Gross, and Sampat https://www.nber.org/papers/w33627

Bild

Tariffs get all the attention, but ask economists what they're really worried about and many will point to the Trump administration's cuts to federal support for the sciences, including canceling grants and revoking student visas. #EconSky www.nytimes.com/2025/03/31/b...

Trump’s Science Policies Pose Long-Term Risk, Economists Warn (Gift Article)

Since World War II, U.S. research funding has led to discoveries that fueled economic gains. Now cutbacks are seen as putting that legacy in jeopardy.

nytimes.com

The US WW2 medical research and development effort catalyzed postwar science, modernized drug discovery, and fueled the postwar National Institutes of Health — reshaping biomedical innovation for decades, from Daniel P. Gross and Bhaven N. Sampat https://www.nber.org/papers/w33457

Bild

A good summary of what's gone on with NSF funding, and some interesting new tidbits. I'm really pleased they chose to end with @wytham88.bsky.social and a link to our paper: “Grants don’t just generate knowledge or output now, they’ve become a way that we support the training of future scientists.”

Dan Garisto@dangaristo.bsky.social · 2y ago

NEW: We obtained the directions NSF program officers are following to review all grants for compliance with the Trump EOs and the turmoil it has created in an agency mandated to broaden STEM participation. Our story: www.nature.com/articles/d41...

Full thread coming soon. If you want a break from current events, come see the talk at the Virtual Seminar on Innovation and Economic Growth this Wednesday 12pm ET! sites.google.com/view/v-s-inn... Kudos to Alex and Murat for creating a new seminar 💪

VSIEG

2025 Winter Schedule: Wednesdays at 12 noon - 1pm Eastern Time. February 5th - Dan Gross (Duke) "The Therapeutic Consequences of the War: World War II and the 20th Century Expansion of Biomedicine ...

sites.google.com

It's such a weird thing to hear the news and think "that's bad, but also I have a paper about (an aspect) of that" Funding delays are really not great for people who work in science. Funding delays of > 30 days lead to: - 40% increase in scientists exiting US labor force - 20% decrease in wages

Carl Zimmer@carlzimmer.com · 2y ago

Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring www.science.org/content/arti...

A golden age not only for antibiotics but also other drugs, and biomedicine broadly -- new paper on the links of this prolific era to the WW2 research effort (& the limits to those links) coming shortly. Lots to think about in the way of possible parallels in the aftermath of Covid and OWS.

BildBild
Saloni@scientificdiscovery.dev · 2y ago

Many people talk about the "Golden Age of Antibiotics", but I hadn't seen it visualized properly. Just how many types of antibiotics were discovered during that time? So, I visualized it myself!

A timeline titled "The Golden Age of Antibiotics" shows when each antibiotic drug class was first available for medical use, with example antibiotics labeled. Classes are color-coded by their source: actinomycetes, other bacteria, fungi, or synthetic. Milestones include the first antibiotics (arsphenamines in 1910), as well as the discovery of many actinomycetes-derived antibiotics, such as streptomycin, and sulfonamides, penicillins, and tetracyclines. Data: Hutchings, Truman, Wilkinson (2019). Created by Saloni Dattani for Our World in Data.